Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Idec (IDPH) said European approval for its Zevalin non-Hodgkin's lymphoma (NHL) radioimmunotherapy has been delayed due to compliance
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury